Table 1. Baseline patient characteristics.
| Group A (n=32) | Group B (n=27) | P value | |
|---|---|---|---|
| Sex | 0.063 | ||
| Male | 22(69%) | 24(89%) | |
| Female | 10(31%) | 3(11%) | |
| Age (years) | 0.128 | ||
| <65 | 17(55%) | 20(74%) | |
| ≥65 | 14(45%) | 7(26%) | |
| Tumor location | 0.933 | ||
| GEJ | 11(34%) | 9(33%) | |
| Other stomach | 21(66%) | 18(67%) | |
| Lauren | 0.867 | ||
| Intestinal | 14(44%) | 10(37%) | |
| Non-intestinal | 5(16%) | 5(19%) | |
| Unknown | 13(40%) | 12(44%) | |
| HER2 status | 0.962 | ||
| IHC3+ | 19(59%) | 16(60%) | |
| IHC2+/FISH+ | 13(41%) | 11(40%) | |
| Number of metastatic organs | 0.432 | ||
| <3 | 23(72%) | 21(81%) | |
| ≥3 | 9(28%) | 5(19%) | |
| Metastatic site | |||
| liver | 20(63%) | 15(56%) | 0.589 |
| Peritoneum | 7(22%) | 9(33%) | 0.324 |
| Lymph node | 23(72%) | 16(59%) | 0.308 |
| ECOG | 0.315 | ||
| 0/1 | 29(91%) | 21(78%) | |
| 2 | 3(9%) | 6(22%) | |
| First-line chemotherapy | 0.127 | ||
| Platinum based | 17(56%) | 9(33%) | |
| Non-platinum based | 15(44%) | 18(67%) | |
| First-line response | 0.614 | ||
| CR/PR | 21(66%) | 16(59%) | |
| SD/PD | 11(34%) | 11(41%) | |
| Second-line chemotherapy | |||
| Fluoropyrimidine based | 18(56%) | 19(70%) | 0.264 |
| Platinum based | 11(34%) | 8(30%) | 0.698 |
| Irinotecan based | 5(19%) | 5(15.6) | 0.518 |
| Taxane/Docetaxel based | 15(47%) | 13(48%) | 0.922 |
| Third-line therapy | 0.483 | ||
| No | 21(66%) | 20(74%) | |
| Yes | 11(34%) | 7(26%) | |
| mTT1 (range, cycles) | 7.5(2-22) | 9.0(2-22) | 0.577* |
| mPFS1 (95%CI, months) | 9.00 (range 6.25-11.75) | 6.60 (range 5.89-7.31) | 0.134# |
*
Mann-Whitney U test,
#
log-rank test
Abbreviation: GEJ, gastric esophagus junction; ECOG, European Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; mPFS1, median progress free survival of first line therapy; mTT1, median cycles of first line trastuzumab therapy.